GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » Total Inventories

Marizyme (Marizyme) Total Inventories : $0.02 Mil (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Marizyme Total Inventories?

Marizyme's total inventories for the quarter that ended in Mar. 2024 was $0.02 Mil. Marizyme's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $0.02 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Marizyme's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.25.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Marizyme's Days Inventory for the three months ended in Mar. 2024 was 182.50.

Inventory Turnover measures how fast the company turns over its inventory within a year. Marizyme's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.50.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Marizyme's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.61.


Marizyme Total Inventories Historical Data

The historical data trend for Marizyme's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marizyme Total Inventories Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.06 0.02 0.22 0.03

Marizyme Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.14 0.10 0.03 0.02

Marizyme Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Marizyme  (OTCPK:MRZM) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Marizyme's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.006+0.75 * 0+0.5 * 0.015-32.403
-0-0)/131.793
=-0.25

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Marizyme's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=0.02/0.01*365 / 4
=182.50

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Marizyme's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=0.01 / 0.02
=0.50

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Marizyme's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0.02 / 0.033
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Marizyme Total Inventories Related Terms

Thank you for viewing the detailed overview of Marizyme's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Marizyme (Marizyme) Business Description

Traded in Other Exchanges
N/A
Address
555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Executives
Braeden Lichti 10 percent owner 650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7
Nilesh Umedbhai Patel director 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Michael R Stewart director 5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044
Harrison Ross officer: Vice President of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Georgiy Kovalyov officer: Chief Financial Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
David Barthel director, officer: Chief Executive Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Bradley Richmond officer: Acting VP of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Julie B. Kampf director 14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410
Vithalbhai D Dhaduk director FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Very Donald Leroy Jr officer: Executive Vice President 4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739
William Hearl director 448 SALK CIRCLE, GAITHERSBERG MD 20878
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Catherine J. Pachuk officer: Chief Science Officer 1033 N. JEAGA DR, JUPITER FL 33458
Satishchandran Chandrasekhar officer: Chief Operating Officer 167 CARMELA COURT, JUPITER FL 33478

Marizyme (Marizyme) Headlines

From GuruFocus

Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

By GuruFocusNews GuruFocusNews 11-16-2021

Marizyme CEO Delivers Business Update

By Marketwired 10-23-2023

Marizyme Signs LOI With Chromocell to Acquire or License Assets

By ACCESSWIRE AccessWire 04-12-2019